A Double Blind (Sponsor Open) Placebo-controlled, Stratified, Parallel Group Study to Evaluate the Efficacy and Safety of Repeat Doses of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2018
At a glance
- Drugs GSK-3772847 (Primary)
- Indications Allergic asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 02 Oct 2018 Planned End Date changed from 14 Aug 2019 to 10 Oct 2019.
- 02 Oct 2018 Planned primary completion date changed from 22 May 2019 to 18 Jul 2019.
- 31 Aug 2018 Biomarkers information updated